GH Research (NASDAQ:GHRS) Trading 4.1% Higher – What’s Next?

Shares of GH Research PLC (NASDAQ:GHRS) rose 4.1% during mid-day trading on Tuesday . The stock traded as high as $9.66 and last traded at $9.41. Approximately 15,035 shares changed hands during mid-day trading, a decline of 81% from the average daily volume of 79,072 shares. The stock had previously closed at $9.04.

Analyst Ratings Changes

Several brokerages have weighed in on GHRS. JMP Securities restated a “market outperform” rating and set a $39.00 price objective on shares of GH Research in a research note on Wednesday, September 4th. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th.

GH Research Stock Up 1.2 %

The company has a market capitalization of $476.06 million, a PE ratio of -14.04 and a beta of 0.74. The firm has a 50-day moving average of $7.74 and a two-hundred day moving average of $10.41.

GH Research (NASDAQ:GHRS) last posted its earnings results on Tuesday, September 3rd. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.03. Equities analysts predict that GH Research PLC will post -0.85 EPS for the current fiscal year.

Hedge Funds Weigh In On GH Research

A hedge fund recently raised its stake in GH Research stock. RA Capital Management L.P. increased its position in GH Research PLC (NASDAQ:GHRS) by 11.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,251,714 shares of the company’s stock after purchasing an additional 664,381 shares during the quarter. RA Capital Management L.P. owned 12.02% of GH Research worth $66,643,000 as of its most recent filing with the Securities and Exchange Commission. 56.90% of the stock is currently owned by institutional investors and hedge funds.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).